Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

1.

Successful mobilization, intra-apheresis recruitment, and harvest of hematopoietic progenitor cells by addition of plerixafor and subsequent large-volume leukapheresis.

Humpe A, Buwitt-Beckmann U, Schub N, Gramatzki M, Günther A.

Transfus Med Hemother. 2013 Aug;40(4):251-7. doi: 10.1159/000354377. Epub 2013 Jul 25.

PMID:
24179473
[PubMed]
Free PMC Article
2.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.

PMID:
22683613
[PubMed - indexed for MEDLINE]
3.

Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

Keating GM.

Drugs. 2011 Aug 20;71(12):1623-47. doi: 10.2165/11206040-000000000-00000. Review.

PMID:
21861545
[PubMed - indexed for MEDLINE]
4.

The use of plerixafor in hematopoietic progenitor cell collection in pediatric patients: a single center experience.

Pham HP, Patel N, Semedei-Pomales M, Bhatia M, Schwartz J.

Cytotherapy. 2012 Apr;14(4):467-72. doi: 10.3109/14653249.2012.658912. Epub 2012 Feb 20.

PMID:
22339604
[PubMed - indexed for MEDLINE]
5.

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.

Fruehauf S, Ehninger G, Hübel K, Topaly J, Goldschmidt H, Ho AD, Müller S, Moos M, Badel K, Calandra G.

Bone Marrow Transplant. 2010 Feb;45(2):269-75. doi: 10.1038/bmt.2009.142. Epub 2009 Jul 13.

PMID:
19597422
[PubMed - indexed for MEDLINE]
6.

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF.

Biol Blood Marrow Transplant. 2008 Sep;14(9):1045-56. doi: 10.1016/j.bbmt.2008.07.004.

PMID:
18721768
[PubMed - indexed for MEDLINE]
7.

Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.

Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R.

Bone Marrow Transplant. 1997 Mar;19(6):529-37.

PMID:
9181898
[PubMed - indexed for MEDLINE]
Free Article
8.

Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma.

Desikan KR, Jagannath S, Siegel D, Nelson J, Bracy D, Barlogie B, Tricot G.

Leuk Lymphoma. 1998 Feb;28(5-6):501-8.

PMID:
9613979
[PubMed - indexed for MEDLINE]
9.

CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.

Cesana C, Carlo-Stella C, Regazzi E, Garau D, Sammarelli G, Caramatti C, Tabilio A, Mangoni L, Rizzoli V.

Bone Marrow Transplant. 1998 Mar;21(6):561-8.

PMID:
9543059
[PubMed - indexed for MEDLINE]
Free Article
10.

The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF.

D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S, Dan E, Taioli S, Giudice V, Agis H, Kopetzky G, Soutar R, Casadei B, Baccarani M, Lemoli RM.

Bone Marrow Transplant. 2011 Mar;46(3):356-63. doi: 10.1038/bmt.2010.128. Epub 2010 May 31.

PMID:
20577218
[PubMed - indexed for MEDLINE]
11.

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.

Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, Calandra G.

Biol Blood Marrow Transplant. 2009 Dec;15(12):1578-86. doi: 10.1016/j.bbmt.2009.08.005. Epub 2009 Oct 4.

PMID:
19896082
[PubMed - indexed for MEDLINE]
12.

Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.

Stewart DA, Smith C, MacFarland R, Calandra G.

Biol Blood Marrow Transplant. 2009 Jan;15(1):39-46. doi: 10.1016/j.bbmt.2008.10.018.

PMID:
19135941
[PubMed - indexed for MEDLINE]
13.

Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.

Tanhehco YC, Adamski J, Sell M, Cunningham K, Eisenmann C, Magee D, Stadtmauer EA, O'Doherty U.

J Clin Apher. 2010;25(4):202-8. doi: 10.1002/jca.20239.

PMID:
20818715
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.

Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweeney PA.

Biol Blood Marrow Transplant. 2011 May;17(5):729-36. doi: 10.1016/j.bbmt.2010.08.018. Epub 2010 Oct 14.

PMID:
20813198
[PubMed - indexed for MEDLINE]
15.

Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: implications for optimal timing of PBPC harvest.

Dettke M, Greinix HT, Kalhs P, Kührer I, Worel N, Höcker P.

Transfusion. 2001 May;41(5):681-6.

PMID:
11346706
[PubMed - indexed for MEDLINE]
16.

Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.

Varmavuo V, Mäntymaa P, Kuittinen T, Nousiainen T, Jantunen E.

Transfus Apher Sci. 2012 Jun;46(3):257-62. doi: 10.1016/j.transci.2012.03.011. Epub 2012 Mar 31.

PMID:
22465758
[PubMed - indexed for MEDLINE]
17.

Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.

Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G.

Biol Blood Marrow Transplant. 2009 Feb;15(2):249-56. doi: 10.1016/j.bbmt.2008.11.028.

PMID:
19167685
[PubMed - indexed for MEDLINE]
18.

Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF.

Fraipont V, Sautois B, Baudoux E, Pereira M, Fassotte MF, Hermanne JP, Jérusalem G, Longrée L, Schaaf-Lafontaine N, Fillet G, Beguin Y.

Transfusion. 2000 Mar;40(3):339-47.

PMID:
10738037
[PubMed - indexed for MEDLINE]
19.

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.

Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED.

Pharmacotherapy. 2012 Jul;32(7):596-603. doi: 10.1002/j.1875-9114.2012.01096.x.

PMID:
22760691
[PubMed - indexed for MEDLINE]
20.

Correlations between hematopoietic progenitor cell counts as measured by Sysmex and CD34+ cell harvest yields following mobilization with different regimens.

Vogel W, Kopp HG, Kanz L, Einsele H.

J Cancer Res Clin Oncol. 2002 Jul;128(7):380-4. Epub 2002 Jun 13.

PMID:
12136252
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk